HC Wainwright Issues Pessimistic Forecast for TC Biopharm (NASDAQ:TCBP) Stock Price

TC Biopharm (NASDAQ:TCBP) had its target price cut by HC Wainwright from $7.00 to $3.00 in a report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 369.48% from the company’s current price.

TC Biopharm Stock Performance

Shares of TCBP opened at $0.64 on Friday. The company’s fifty day moving average is $2.49 and its 200 day moving average is $5.84. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.88 and a current ratio of 1.12. TC Biopharm has a fifty-two week low of $0.44 and a fifty-two week high of $73.00.

TC Biopharm Company Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.